- Home
- ZKH vs OPT Comparison
ZKH vs OPT Comparison
Compare ZKH & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZKH
- OPT
- Stock Information
- Founded
- ZKH 1998
- OPT 1984
- Country
- ZKH China
- OPT Australia
- Employees
- ZKH N/A
- OPT N/A
- Industry
- ZKH
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZKH
- OPT Health Care
- Exchange
- ZKH Nasdaq
- OPT Nasdaq
- Market Cap
- ZKH 588.1M
- OPT 574.0M
- IPO Year
- ZKH 2023
- OPT 2020
- Fundamental
- Price
- ZKH $3.56
- OPT $3.90
- Analyst Decision
- ZKH Strong Buy
- OPT Strong Buy
- Analyst Count
- ZKH 2
- OPT 1
- Target Price
- ZKH $12.65
- OPT $12.00
- AVG Volume (30 Days)
- ZKH 38.6K
- OPT 18.3K
- Earning Date
- ZKH 11-22-2024
- OPT 02-26-2025
- Dividend Yield
- ZKH N/A
- OPT N/A
- EPS Growth
- ZKH N/A
- OPT N/A
- EPS
- ZKH N/A
- OPT N/A
- Revenue
- ZKH $1,259,541,805.00
- OPT $261,859.00
- Revenue This Year
- ZKH $0.49
- OPT N/A
- Revenue Next Year
- ZKH $12.88
- OPT $46,864.26
- P/E Ratio
- ZKH N/A
- OPT N/A
- Revenue Growth
- ZKH 3.49
- OPT N/A
- 52 Week Low
- ZKH $2.62
- OPT $1.79
- 52 Week High
- ZKH $21.91
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- ZKH 50.73
- OPT 56.41
- Support Level
- ZKH $3.50
- OPT $3.59
- Resistance Level
- ZKH $3.90
- OPT $3.90
- Average True Range (ATR)
- ZKH 0.24
- OPT 0.24
- MACD
- ZKH 0.01
- OPT 0.02
- Stochastic Oscillator
- ZKH 49.26
- OPT 74.11
About ZKH ZKH Group Limited each representing thirty-five (35)
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.